Drug pricing

News

CMS extends list of drugs with penalties for price hikes

In a new update, the US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation.

News

Merck sues US govt over Inflation Reduction Act

Pharma industry anger at US legislation that gives Medicare the power to negotiate drug prices has spilled over into the courts.

News

Mark Cuban will offer low-cost Humira thanks to Coherus deal

Billionaire and celebrity entrepreneur Mark Cuban has revealed his latest move to tackle the cost of medicines in the US, agreeing a deal to make a low-cost biosimilar ver

Sales & Marketing

How transparent is the VPAS?

The UK’s VPAS – a deal that began on 1st January 2019 and which is due to end on 31st December 2023 – is worth around £7 billion.

News

CMS plan would shine light on Medicaid drug pricing

A proposal by the US Department of Health and Human Services (HHS) would expose the actual costs of drugs covered by Medicaid, and hold manufacturers to account for the am

News

UK generics body makes bid to join voluntary scheme talks

The UK’s voluntary system of revenue rebates to limit rises in medicines spending is already causing deep upset among branded drug manufacturers as clawbacks rise.

CMS extends list of drugs with penalties for price hikes

Merck sues US govt over Inflation Reduction Act

Mark Cuban will offer low-cost Humira thanks to Coherus deal

How transparent is the VPAS?

CMS plan would shine light on Medicaid drug pricing

UK generics body makes bid to join voluntary scheme talks

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Drug pricing

Editor's Picks